Program Announcement

for the

Defense Health Program

Department of Defense

Congressionally Directed Medical Research Programs

Prostate Cancer Research Program

Idea Development Award

Funding Opportunity Number: W81XWH-13-PCRP-IDA
Catalog of Federal Domestic Assistance Number: 12.420

SUBMISSION AND REVIEW DATES AND TIMES

- Pre-Application Submission Deadline: 5:00 p.m. Eastern time (ET), June 19, 2013
- Invitation to Submit an Application: August 8, 2013
- Application Submission Deadline: 11:59 p.m. ET, October 2, 2013
- Peer Review: December 2013
- Programmatic Review: February 2014

This Program Announcement is one of two documents with instructions to prepare and submit an application for this funding opportunity. The second document, the General Application Instructions, is available for downloading from Grants.gov.
TABLE OF CONTENTS

I. Funding Opportunity Description ................................................................. 3
   A. Program Description ..............................................................................3
   B. Award Information ..............................................................................4
   C. Eligibility Information .......................................................................5
   D. Funding ..............................................................................................6

II. Submission Information ............................................................................... 7
   A. Where to Obtain the Application Package ..........................................7
   B. Pre-Application Submission Content and Form ..................................7
   C. Application Submission Content and Form ..........................................10
   D. Submission Dates and Times ..............................................................15
   E. Other Submission Requirements .........................................................15

III. Application Review Information ................................................................. 15
   A. Application Review and Selection Process ........................................15
   B. Application Review Criteria ...............................................................16
   C. Recipient Qualification ....................................................................17
   D. Application Review Dates .................................................................17
   E. Notification of Application Review Results .......................................17

IV. Administrative Actions ............................................................................. 18
   A. Rejection ...........................................................................................18
   B. Modification .......................................................................................18
   C. Withdrawal ........................................................................................18
   D. Withhold ............................................................................................19

V. Award Administration Information ............................................................ 19
   A. Award Notice ......................................................................................19
   B. Administrative and National Policy Requirements ..........................19
   C. Reporting ............................................................................................19
   D. Award Transfers ...............................................................................20

VI. Agency Contacts ....................................................................................... 20
   A. CDMRP Help Desk .............................................................................20
   B. Grants.gov Contact Center ...............................................................20

VII. Application Submission Checklist ........................................................... 21
I. FUNDING OPPORTUNITY DESCRIPTION

A. Program Description

Applications to the Fiscal Year 2013 (FY13) Prostate Cancer Research Program (PCRP) are being solicited for the Assistant Secretary of Defense for Health Affairs, Defense Health Program (DHP), by the U.S. Army Medical Research Acquisitions Activity (USAMRAA). The PCRP was initiated in 1997 to promote innovative research focused on eradicating prostate cancer. Appropriations for the PCRP from FY97 through FY12 totaled $1.21 billion. The FY13 appropriation is $80 million (M).

The mission of the FY13 PCRP is to find and fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of men experiencing the impact of the disease. Specifically, the PCRP seeks to promote highly innovative, groundbreaking research; high-impact research with near-term clinical relevance; multidisciplinary, synergistic research; translational studies to support the fluid transfer of knowledge between bedside and bench; research on patient survivorship and quality of life; the next generation of prostate cancer investigators through mentored research; and research on disparities in the incidence and mortality of prostate cancer.

PCRP Overarching Challenges (revised for FY13)

Consistent with the program’s mission to eliminate death from prostate cancer and enhance the well-being of men experiencing the impact of the disease, including those from disproportionately affected populations, each PCRP funding opportunity either requires or encourages (see Section I.B., Award Information below) applications to address one of the following three PCRP overarching challenges:

- Develop better tools to detect clinically relevant disease in asymptomatic men
- Distinguish aggressive from indolent disease in men newly diagnosed with prostate cancer
- Develop effective treatments and address mechanisms of resistance for men with high risk or metastatic prostate cancer

PCRP Focus Areas (revised for FY13)

All applications for FY13 PCRP funding opportunities are also expected to address at least one of the following PCRP focus areas:

- **Biomarker Development:** Validation and qualification of biomarkers for early detection of clinically relevant disease or for prognosis or prediction and assessment of response to therapies
- **Genetics:** Understanding host or tumor genetics and epigenetics responsible for susceptibility, disease progression, and treatment outcomes for clinically relevant prostate cancer
- **Imaging:** Development of new anatomic, functional, and molecular imaging approaches for the detection and management of clinically relevant prostate cancer
• **Mechanisms of Resistance:** Understanding primary and acquired resistance to therapy

• **Survivorship and Palliative Care:** Improving the quality of life and well-being of prostate cancer patients and their families

• **Therapy:** Identification of new targets, pathways, and therapeutic modalities

• **Tumor and Microenvironment Biology:** Understanding the intrinsic and extrinsic mechanisms contributing to tumor development and the progression of prostate cancer

**B. Award Information**

The PCRP Idea Development Award mechanism was first offered in FY97. Since then, 5,748 Idea Development Award applications have been received, and 1,029 have been recommended for funding.

The Idea Development Award supports new ideas that represent innovative approaches to prostate cancer research and have the potential to make an important contribution to the PCRP mission. Although groundbreaking research often involves a degree of risk, applications should be based on a sound scientific rationale that is established through logical reasoning and/or critical review and analysis of the literature. Due to this award’s emphasis on innovation, the presentation of preliminary data relevant to prostate cancer and the proposed project is encouraged but not required. Research deemed innovative may represent a new paradigm, challenge current paradigms, look at existing problems from new perspectives, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative.

The PCRP seeks applications from the wide spectrum of basic, population-based, translational, and clinical research. **In addition, applicants are expected to address at least one of the PCRP focus areas and are highly encouraged to address one of the PCRP overarching challenges.** If the proposed project does not address any of the overarching challenges, the application should include a description to justify how the project will nevertheless address a critical need in the field of prostate cancer research and/or patient care.

**New Investigator Option:** The FY13 Idea Development Award mechanism encourages applications from investigators in the early stages of their careers. The New Investigator Option is designed to allow applicants **early in their faculty appointments, or in the process of developing independent research careers,** to compete for funding separately from established investigators. Applications from New Investigators and Established Investigators will be peer- and programatically reviewed in separate groups. PIs using the New Investigator Option are strongly encouraged to strengthen their applications through collaboration with investigators experienced in prostate cancer research and/or possessing other relevant expertise. It is the responsibility of the PI to describe how collaboration will augment his or her expertise to best address the research question. All applicants for the New Investigator Option must meet specific eligibility criteria as described in Section I.C., Eligibility Information.
Research involving human subjects is encouraged under this funding opportunity but is restricted to studies without clinical trials. Correlative studies associated with an existing clinical trial are encouraged if they are determined to be no greater than minimal risk by the local IRB of record and the U.S. Army Medical Research and Materiel Command (USAMRMC) Office of Research Protections (ORP), Human Research Protection Office (HRPO). For definitions and other information on clinical trials and clinical research overall, a Human Subject Resource Document is provided on the CDMRP eReceipt System at https://cdmrp.org/Program_Announcements_and_Forms/.

All investigators applying to FY13 PCRP funding opportunities are encouraged to consider leveraging resources available through the PCRP-funded Prostate Cancer Biorepository Network (PCBN) (http://www.prostatebiorepository.org) and/or the North Carolina – Louisiana Prostate Cancer Project (PCaP) (http://www.ncla-pcap.org) if retrospectively collected human anatomical substances or correlated data are relevant to the proposed studies.

The Congressionally Directed Medical Research Programs (CDMRP) intends that data and research resources generated under awards funded by this Program Announcement/Funding Opportunity be made available to the research community (which includes both scientific and consumer advocacy communities) and to the public at large. For additional guidance, refer to the General Application Instructions, Appendix 4, Section K.

C. Eligibility Information

Although a PI may be eligible for both the Established Investigator and New Investigator Option categories, the PI can choose only one category under which to apply. If this is the case, the choice of application category is at the PI’s discretion.

- **Established Investigator**
  
The PI must be an independent investigator at or above the level of Assistant Professor (or equivalent).

- **New Investigator Option**
  
  By the application submission deadline date, the PI must have:
  
  - The freedom to pursue independent research goals without formal mentorship;
  - Not previously received a PCRP Idea Development Award; and
  - Either completed at least 3 years of postdoctoral training or fellowship or been in an independent faculty position for less than 5 years.

  New Investigators working within a laboratory team are eligible to apply for this award provided they can demonstrate that they have the freedom to pursue independent research goals without formal mentorship. Graduate students and junior postdoctoral fellows (i.e., fellows with less than 3 years postdoctoral training) are not eligible for this award.
• Cost sharing/matching is not an eligibility requirement.
• Organizations eligible to apply include national, international, for-profit, non-profit, public, and private organizations.
• Refer to the General Application Instructions, Appendix 1, for general eligibility information.

D. Funding
• The maximum period of performance is 3 years.
• The maximum allowable direct costs for the entire period of performance are $375,000 plus indirect costs for Established Investigators. If applying for the New Investigator Option, the maximum allowable direct costs amount for the entire period of performance are $225,000 plus indirect costs.
• All direct and indirect costs of any subaward (subgrant or subcontract) must be included in the total direct costs of the primary award.
• The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 3 years.
• Regardless of the period of performance proposed, the applicant may not exceed the maximum allowable direct costs. Indirect costs shall be proposed in accordance with the organization’s negotiated rate agreement.

Refer to the General Application Instructions, Section II.C.4., for budget regulations and instructions for the Research & Related Budget. *For all federal agencies or organizations collaborating with federal agencies, budget restrictions apply as are noted in Section II.C.4. of the General Application Instructions.*

In addition, for this award mechanism, direct costs:

Must be requested for:

• Travel for attendance at one Department of Defense (DoD) PCRP Innovative Minds in Prostate Cancer Today (IMPaCT) meeting, which is held to disseminate the results of PCRP-sponsored research. Costs associated with travel to this meeting, up to $1,800, should be included in Year 2 of the budget. For planning purposes, it should be assumed that the meeting will be held in the National Capital Area. These travel costs are in addition to those allowed for annual scientific/technical meetings.

May be requested for (not all-inclusive):

• Salary
• Research supplies
• Equipment
• Clinical research costs (other than costs for clinical trials, which are not allowed)
• Travel between collaborating organizations
• Travel costs of up to $1,800 per year to attend scientific/technical meetings in addition to the required meeting described above

The CDMRP expects to allot approximately $17.3M of the $80M FY13 PCRP appropriation to fund approximately 24 Established Investigator and 8 New Investigator Idea Development Award applications, depending on the quality and number of applications received. Funding of applications received in response to this Program Announcement/Funding Opportunity is contingent upon the availability of federal funds for this program.

II. SUBMISSION INFORMATION

Submission is a two-step process requiring both (1) pre-application submission through the CDMRP eReceipt System (https://cdmrp.org/) and (2) application submission through Grants.gov (http://www.grants.gov/).

Submission of applications that are essentially identical or propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application.

A. Where to Obtain the Application Package

To obtain the complete application package, including all required forms, perform a Grants.gov (http://www.grants.gov/) basic search using the Funding Opportunity Number: W81XWH-13-PCRP-IDA.

B. Pre-Application Submission Content and Form

All pre-application components must be submitted by the PI through the CDMRP eReceipt System (https://cdmrp.org/). Because the invitation to submit an application is based on the contents of the pre-application, investigators should not change the title or research objectives after the pre-application is submitted.

PIs and organizations identified in the pre-application should be the same as those intended for the subsequent application submission. If any changes are necessary after submission of the pre-application, the PI must contact the CDMRP Help Desk at help@cdmrp.org or 301-682-5507.

When starting the pre-application, PIs should ensure that they have selected the appropriate application category, i.e., “Idea Development Award - Established Investigator” OR “Idea Development Award - New Investigator Option.”

The pre-application consists of the following components, which are organized in the CDMRP eReceipt System by separate tabs (refer to the General Application Instructions, Section II.B., for additional information on pre-application submission):

• Application Information – Tab 1
• Application Contacts – Tab 2
**Collaborators and Conflicts of Interest (COI) – Tab 3**

FY13 PCRP Integration Panel (IP) members should not be involved in any preapplication or application. A list of FY13 PCRP IP members can be found at http://cdmrp.army.mil/pcrp/panels/panel13. For questions related to IP members and pre-applications or applications, refer to Section IV.C., Withdrawal, or contact the CDMRP Help Desk at help@cdmrp.org or 301-682-5507.

**Required Files – Tab 4**

**Preproposal Narrative (two-page limit):** The Preproposal Narrative page limit applies to text and any non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings, etc.) used to describe the proposed project. The presentation of preliminary data is not required; however, logical reasoning and a sound scientific rationale must be provided. Inclusion of URLs that provide additional information to expand the Preproposal Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the application. 

*Note: At this time, eReceipt is unable to read files made with Adobe Acrobat PDFMaker version 9.0 and higher.*

Pre-applications will be screened based on the merits of the proposed research. Therefore, reviewers will be blinded to the identity of the PI, collaborators, and their organizations(s). Due to the blinded nature of the review process, identifying or making references to the PI, collaborators, or their organization(s) within the Preproposal Narrative is prohibited and will result in administrative rejection of the pre-application and preclude invitation to submit a full application. In addition, the use of “I,” “we,” “our,” “this organization,” or similar wording in phrases that refer to the PI, collaborators, or their organization(s) through the references listed will also result in administrative rejection of the pre-application and preclude invitation to submit a full application.

The Preproposal Narrative should describe the proposed project using the outline below:

- **Rationale:** Clearly articulate the rationale for the project by presenting the ideas and reasoning that support it; include relevant literature citations.
- **Hypothesis or Objective:** State the hypothesis to be tested or the objective to be reached.
- **Research Approach:** State the project’s specific aims and briefly describe the experimental approach to accomplishing the aims. *This award cannot be used to conduct clinical trials.*
- **Innovation:** Describe how the proposed study is innovative.
- **Impact:** Describe the potential short-term and long-term impact of this study on prostate cancer research and/or patient care. Research that has high impact will, if successful, significantly accelerate progress toward the elimination of death from prostate cancer and enhancing the well-being of men experiencing the impact of the disease.
Overarching Challenges and Focus Areas: Briefly describe how the proposed research is relevant to one or more of the PCRP focus areas and responsive to one of the PCRP overarching challenges. If the proposed project does not address any of the overarching challenges, provide a description to justify how the project will nevertheless significantly address a critical need in the field of prostate cancer research and/or patient care.

Pre-Application Supporting Documentation: The items to be included as supporting documentation for the pre-application are limited to:

1. References Cited (one-page limit): List the references cited (including URLs if available) in the Preproposal Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate). Do not include publication URLs that identify the organization(s) of the PI or collaborator.

2. List of Abbreviations, Acronyms, and Symbols: Provide a list of abbreviations, acronyms, and symbols used in the Preproposal Narrative. Do not include information that identifies the organization(s) of the PI or any collaborators.

3. (New Investigator Option Only) PI Biographical Sketches (two-page limit): Include a biographical sketch for the PI. Biosketches will be reviewed administratively to confirm eligibility but will not be included in the merit-based pre-application screening.

Submit Pre-Application – Tab 5
This tab must be completed for the pre-application to be accepted and processed by CDMRP.

Other Documents Tab
No additional documents are required.

Pre-Application Screening

Pre-Application Screening Criteria
To determine the technical merits of the pre-application and the relevance to the mission of the DHP and the PCRP, pre-applications will be screened by peer review based on the criteria below. Of these, Innovation and Impact are equally most important, with the remaining criteria listed in decreasing order of importance.

1. Innovation: To what degree the proposed research is highly creative and represents more than an incremental advance upon published data.

2. Impact: To what degree the proposed study could, whether short-term or long-term, make a significant impact on prostate cancer research and/or patient care, including its potential contribution to the elimination of death from prostate cancer and enhancing the well-being of men experiencing the impact of the disease.
Research Approach: To what degree the experimental approach for accomplishing the specific aims is feasible and addresses the hypothesis or objective.

Responsiveness to Overarching Challenges: To what degree the proposed research is responsive to one of the PCRP overarching challenges or is otherwise justified as addressing another critical issue in prostate cancer research and/or patient care.

Notification of Pre-Application Screening Results

Following the pre-application screening, PIs will be notified as to whether or not they are invited to submit applications; however, they will not receive feedback (e.g., a critique of strengths and weaknesses) on their pre-application. The estimated timeframe for notification of invitation to submit an application is indicated on the title page of this Program Announcement/Funding Opportunity.

C. Application Submission Content and Form

Applications will not be accepted unless the PI has received notification of invitation.

Each application submission must include the completed application package of forms and attachments provided in Grants.gov for this Program Announcement/Funding Opportunity. The application package is submitted by the Authorized Organizational Representative through the Grants.gov portal (http://www.grants.gov/).

Grants.gov application package components: For the Idea Development Award, the Grants.gov application package includes the following components (refer to the General Application Instructions, Section II.C., for additional information on application submission):

1. SF 424 (R&R) Application for Federal Assistance Form: Refer to the General Application Instructions, Section II.C., for detailed information.

2. Attachments Form

- Attachment 1: Project Narrative (10-page limit): Upload as “ProjectNarrative.pdf.” The page limit of the Project Narrative applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings, etc.) used to describe the project. Inclusion of URLs that provide additional information to expand the Project Narrative and could confer an unfair competitive advantage is prohibited and will result in administrative withdrawal of the application.

Describe the proposed project in detail using the outline below. The inclusion of preliminary data relevant to prostate cancer and the proposed project is encouraged but not required. Any preliminary data provided should be from the laboratory of the PI or member(s) of the collaborating team.

- Background: Present the ideas and reasoning behind the proposed research; include relevant literature citations. Describe previous experience most pertinent to this application.
○ **Hypothesis or Objective:** State the hypothesis to be tested or the objective to be reached.

○ **Specific Aims:** Concisely explain the project’s specific aims. If this application is part of a larger study, present only tasks that this award would fund.

○ **Research Strategy:** Describe the experimental design, methods, and analyses, including appropriate controls, in sufficient detail for analysis. Address potential problem areas and present alternative methods and approaches. If human subjects or human biological samples will be used, include a detailed plan for the recruitment of subjects or the acquisition of samples. *This award cannot be used to conduct clinical trials.*

○ **Collaboration (if applicable; encouraged for the New Investigator Option):** Describe the specific contributions of the collaborator(s) to the research project.

○ **Overarching Challenges and Focus Areas:** Describe how the proposed research is relevant to one or more of the PCRP focus areas and responsive to one of the PCRP overarching challenges. If the proposed project does not address any of the overarching challenges, provide a description to justify how the project will nevertheless significantly address a critical need in the field of prostate cancer research and/or patient care.

- **Attachment 2: Supporting Documentation.** Start each document on a new page. Combine and upload as a single file named “Support.pdf.” If documents are scanned to pdf, the lowest resolution (100 to 150 dpi) should be used. *There are no page limits for any of these components unless otherwise noted. Include only those components described below; inclusion of items not requested may result in the removal of those items or administrative withdrawal of the application.*

  ○ References Cited: List the references cited (including URLs if available) in the project narrative using a standard reference format that includes the full citation (i.e., author[s], year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate).

  ○ List of Abbreviations, Acronyms, and Symbols: Provide a list of abbreviations, acronyms, and symbols.

  ○ Facilities, Existing Equipment, and Other Resources: Describe the facilities and equipment available for performance of the proposed project and any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether or not Government-furnished facilities or equipment are proposed for use. If so, reference should be made to the original or present Government award under which the facilities or equipment items are now accountable. There is no form for this information.

  ○ Publications and/or Patent Abstracts (five-document limit): Include relevant publication URLs and/or patent abstracts. If publications are not publicly available, then a copy/copies of the published manuscript(s) must be included in Attachment 2. Extra items will not be reviewed.
○ Letters of Organizational Support: Provide a letter (or letters, if applicable), signed by the Department Chair or appropriate organization official, confirming the laboratory space, equipment, and other resources available for the project.

○ Letters of Collaboration:
  - **New Investigator Option (if applicable):** Provide a signed letter from each collaborating individual or organization that describes how he/she will support the project, to include unique expertise and/or availability of and access to research resources. If the PI is likely to change organizations during the award period of performance (e.g., New Investigators transitioning into their first independent faculty position), describe how any proposed collaborations will be maintained.
  - **Other:** For all other investigators, provide a signed letter from each collaborating individual or organization (if applicable) that specifically describes the support to be provided.

○ Intellectual Property and Material Property Plan (if applicable): Provide a plan for resolving intellectual and material property issues among participating organizations.

○ Data and Research Resources Sharing Plan: Describe how data and resources generated during the performance of the project will be shared with the research community. Refer to the General Application Instructions, Appendix 4, for more information about the CDMRP expectations for making data and research resources publicly available.

- **Attachment 3: Technical Abstract (one-page limit):** Upload as “TechAbs.pdf.”

  The technical abstract is used by all reviewers. Programmatic reviewers do not typically have access to the full application and therefore rely on the technical abstract for appropriate description of the project’s key aspects. Therefore clarity and completeness within the space limits of the technical abstract are highly important.

  Describe the proposed research project including the following elements:

  ○ **Background:** Present the ideas and reasoning behind the proposed project.

  ○ **Objective:** State the objective to be reached. Provide evidence or rationale that supports the objective.

  ○ **Specific Aims:** State the specific aims of the study.

  ○ **Study Design:** Briefly describe the study design.

  ○ **Impact:** Summarize the potential impact of the proposed project on the elimination of death from prostate cancer and/or enhancing the well-being of men experiencing the impact of the disease.
• **Attachment 4: Lay Abstract (one-page limit):** Upload as “LayAbs.pdf.”

Lay abstracts should be written using the outline below. Do not duplicate the technical abstract. Minimize use of acronyms and abbreviations, where appropriate. The lay abstract is an important component of the application review process because it addresses issues of particular interest to the consumer advocate community.

- Describe the scientific objective and rationale for the proposed project in a manner that will be **readily understood by readers without a background in science or medicine.**
- Describe the ultimate applicability of the research.
  - What types of patients will it help, and how will it help them?
  - What are the potential clinical applications, benefits, and risks?
  - What is the projected time it may take to achieve a patient-related outcome?
  - If the research is too basic for clinical applicability, describe the interim outcomes.
- What are the likely contributions of this study to advancing the field of prostate cancer research?

• **Attachment 5: Statement of Work (SOW) (three-page limit):** Upload as “SOW.pdf.” Refer to the General Application Instructions, Section II.C., for detailed information, including guidance on appropriate SOW formats.

• **Attachment 6: Impact Statement (one-page limit).** Upload as “Impact.pdf.”

Explain in detail why the proposed research project is important, as follows:

**Describe the short-term impact:** Detail the anticipated outcome(s)/product(s) that will be directly attributed to the results of the proposed research.

**Describe the long-term impact:** Explain the anticipated long-term gains from the proposed research, including the long-term anticipated advantages that the new understanding may ultimately contribute to the goal of elimination of death from prostate cancer and enhancing the well-being of men experiencing the impact of the disease.

**PCRP overarching challenges:** Summarize how the proposed project addresses one of the PCRP overarching challenges. If the proposed project does not address any of the overarching challenges, provide a description to justify how the project will nevertheless significantly address a critical need in the field of prostate cancer research and/or patient care.

• **Attachment 7: Innovation Statement (one-page limit).** Upload as “Innovation.pdf.”

Describe how the proposed work is innovative. Research that represents an incremental advancement on published data is not considered innovative.
The following examples of ways in which the proposed work may be innovative, although not all-inclusive, are intended to help the PI frame the innovative features of his/her application:

- Study concept – Investigation of a novel idea and/or research question.
- Research method or technology – Use of novel research methods or new technologies, including technology development, to address a research question.
- Novel method or technology – Development of a novel method or technology for prevention, detection, diagnosis, or treatment.
- Existing methods or technologies – Application or adaptation of existing methods or technologies for novel research or clinical purposes, or for research or clinical purposes that differ fundamentally from those originally intended.

- **Attachment 8: (New Investigator Option only): Eligibility Statement (one-page limit).** Upload as “Eligibility.pdf.”
  
  Use the Eligibility Statement template (available for download on the Full Announcement page in Grants.gov) signed by the Department Chair, Dean, or equivalent official to verify that the eligibility requirements will be met at the application submission deadline.

- **Attachment 9: (New Investigator Option, only for investigators not yet in an independent faculty position): Statement of Independence (one-page limit).** Upload as “Independence.pdf.”

  For investigators not yet in an independent faculty position, complete and sign the Statement of Independence template (available for download on the Full Announcement page in Grants.gov). The Statement of Independence must also be signed by the investigator’s current mentor/supervisor.

3. **Research & Related Senior/Key Person Profile (Expanded):** Refer to the General Application Instructions, Section II.C., for detailed information. **Note: Some of the items in this attachment may be made available for programmatic review.**

- PI Biographical Sketch (four-page limit): Upload as “Biosketch_LastName.pdf.”
- PI Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf.”
- Key Personnel Biographical Sketches (four-page limit each): Upload as “Biosketch_LastName.pdf.”
- Key Personnel Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf.”

4. **Research & Related Budget:** Refer to the General Application Instructions, Section II.C., for detailed information.

- Budget Justification (no page limit): Upload as “BudgetJustification.pdf.”
5. **Project/Performance Site Location(s) Form:** Refer to the General Application Instructions, Section II.C., for detailed information.

6. **R & R Subaward Budget Attachment(s) Form (if applicable):** Refer to the General Application Instructions, Section II.C., for detailed information.

**D. Submission Dates and Times**

All submission dates and times are indicated on the title page of this Program Announcement/Funding Opportunity. Pre-application and application submissions are required. Failure to meet any one of the deadlines will result in application rejection.

**E. Other Submission Requirements**

Refer to the General Application Instructions, Appendix 2, for detailed formatting guidelines. All applications must be submitted through Grants.gov. Applicant organizations and all subrecipient organizations must have a Data Universal Numbering System (DUNS) number to submit applications to Grants.gov. The applicant organization must also be registered in the Entity Management functional area of the System for Award Management (SAM) with an “Active” status to submit applications through the Grants.gov portal. Refer to the General Application Instructions, Appendix 3, for information on Grants.gov requirements.

**III. APPLICATION REVIEW INFORMATION**

**A. Application Review and Selection Process**

All applications are evaluated by scientists, clinicians, and consumer advocates using a two-tier review process. The first tier is a peer review of applications against established criteria for determining technical merit. The second tier is a programmatic review that makes recommendations for funding to the Commanding General, USAMRMC, based on technical merit, the relevance to the mission of the DHP and PCRP, and the specific intent of the award mechanism. The highest-scoring applications from the first tier of review are not automatically recommended for funding. Additional information about the two-tier review process used by the CDMRP can be found at [http://cdmrp.army.mil/about/fundingprocess](http://cdmrp.army.mil/about/fundingprocess).

All CDMRP review processes are conducted confidentially to maintain the integrity of the merit-based selection process. Panel members sign a non-disclosure statement that application and evaluation information will not be disclosed outside the panel. Violations of confidentiality can result in the dissolving of a panel(s) and other corrective actions. In addition, personnel at the applicant or collaborating organizations are prohibited from contacting persons involved in the review process to gain protected evaluation information or to influence the evaluation process. Violations of these prohibitions will result in the administrative withdrawal of the organization’s application. Violations by panel members or applicants that compromise the confidentiality of the review process may also result in suspension or debarment from federal awards. Furthermore, the unauthorized disclosure of confidential information of one party to another third party is a crime in accordance with Title 18 United States Code 1905.
B. Application Review Criteria

1. **Peer Review:** To determine technical merit, all applications will be evaluated according to the following scored criteria; of these, Innovation and Impact are equally the most important, with the remaining criteria listed in decreasing order of importance:

   - **Innovation**
     - How the research proposes new paradigms, challenges existing paradigms, or is otherwise highly creative in one or more of the following ways: Concept or question, research methods or technologies, adaptations of existing methods or technologies, or other ways.
     - To what degree the level of innovation in the proposed research represents more than an incremental advance upon published data.

   - **Impact**
     - How the proposed study could, whether in the short or long term, make a significant impact on prostate cancer research and/or patient care, including its potential contribution to the elimination of death from prostate cancer and enhancing the well-being of men experiencing the impact of the disease.
     - How well the proposed research addresses one of the PCRP overarching challenges or is otherwise justified as significantly addressing another critical issue in prostate cancer research and/or patient care.

   - **Research Strategy and Feasibility**
     - How well the scientific rationale supports the project and its feasibility as demonstrated by a critical review and analysis of the literature, prostate cancer-relevant preliminary data, and/or logical reasoning.
     - How well the hypotheses or objectives, aims, experimental design, methods, and analyses, including statistical analyses as applicable, are developed.
     - How well the PI acknowledges potential problems and addresses alternative approaches.

   - **Personnel**
     - How the research team’s background and prostate cancer-related expertise are appropriate with respect to its ability to perform the proposed work.
     - To what degree the levels of effort are appropriate for successful conduct of the proposed work.
     - **New Investigator Option only:**
       - How the PI’s record of accomplishment demonstrates his/her potential for contributing to the prostate cancer research field and completing the proposed work.
       - If applicable, how well the proposed contributions of collaborators will complement the New Investigator’s ability to perform the proposed work.
In addition, the following unscored criteria will also contribute to the overall evaluation of the application:

- **Environment**
  - To what degree the scientific environment is appropriate for the proposed research.
  - How well the research requirements are supported by the availability of and accessibility to facilities and resources (including collaborative arrangements).
  - To what degree the quality and extent of organizational support are appropriate.

- **Budget**
  - Whether the budget is appropriate for the proposed research and within the limitations of this Program Announcement/Funding Opportunity.

- **Application Presentation**
  - To what extent the writing, clarity, and presentation of the application components influenced the review.

2. **Programmatic Review:** To make funding recommendations, the following equally considered criteria are used by programmatic reviewers:
   
a. **Ratings and evaluations of the peer reviewers**

b. **Relevance to the mission of the DHP and FY13 PCRP, as evidenced by the following:**
   - Adherence to the intent of the award mechanism
   - Programmatic relevance in relation to the PCRP overarching challenges and focus areas
   - Relative impact and innovation
   - Program portfolio composition

C. **Recipient Qualification**

For general information on required qualifications for award recipients, refer to the General Application Instructions, Appendix 1.

D. **Application Review Dates**

All application review dates and times are indicated on the title page of this Program Announcement/Funding Opportunity.

E. **Notification of Application Review Results**

Each PI and organization will receive notification of the funding recommendation. Each PI will receive a peer review summary statement on the strengths and weaknesses of the application.
IV. ADMINISTRATIVE ACTIONS

After receipt of pre-applications from the CDMRP eReceipt System or applications from Grants.gov, the following administrative actions may occur:

A. Rejection

The following will result in administrative rejection of the pre-application:

- Preproposal Narrative exceeds page limit.
- Preproposal Narrative is missing.
- PI or collaborator’s name or organization is included in the Preproposal Narrative or List of Abbreviations, Acronyms, and Symbols.
- Use of “I,” “our,” “we,” “this institution,” or similar phrases in the Preproposal Narrative that refer to the PI, collaborators, and/or their organizations in the references listed.

The following will result in administrative rejection of the application:

- Submission of an application for which a letter of invitation was not received.
- Project Narrative exceeds page limit.
- Project Narrative is missing.
- Budget is missing.
- Submission of the same research project to different funding opportunities within the same program and fiscal year.

B. Modification

- Pages exceeding the specified limits will be removed prior to review for all documents other than the Preproposal Narrative and Project Narrative.
- Documents not requested will be removed.
- Following the application deadline, the PI may be contacted by CDMRP via email with a request to provide certain missing supporting documents (excluding those listed in Section IV.A., Rejection). The missing documents must be provided by 5:00 p.m. ET on the second full business day following the date the email was sent. Otherwise, the application will be reviewed as submitted.

C. Withdrawal

The following may result in administrative withdrawal of the pre-application or application:

- A FY13 PCRP IP member is named as being involved in the research proposed or is found to have assisted in the pre-application or application processes including, but not limited to, concept design, application development, budget preparation, and the development of any supporting document. A list of the FY13 PCRP IP members can be found at [http://cdmrp.army.mil/pcrp/panels/panel13](http://cdmrp.army.mil/pcrp/panels/panel13).
• The application does not conform to this Program Announcement/Funding Opportunity description to an extent that precludes appropriate review.

• Direct costs as shown on the Research & Related Budget exceed the maximum allowed by this Program Announcement/Funding Opportunity.

• Inclusion of URLs, with the exception of links in References Cited and Publication and/or Patent Abstract sections.

• Page size is larger than 8.5 inches x 11.0 inches (approximately 21.59 cm x 27.94 cm).

• Inclusion of any employee of CDMRP review contractors in applications for funding without adequate plans to mitigate conflicts of interest. Refer to the General Application Instructions, Section II.B., for detailed information.

• Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review process to gain protected evaluation information or to influence the evaluation process.

• The proposed research is, or requests funding for, a clinical trial.

• The PI does not meet the eligibility criteria as described in this Program Announcement/Funding Opportunity.

D. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending institutional investigation. The institution will be required to provide the findings of the investigation to the USAMRAA Grants Officer for a determination of the final disposition of the application.

V. AWARD ADMINISTRATION INFORMATION

A. Award Notice

Awards will be made no later than September 30, 2014. Refer to the General Application Instructions, Appendix 4, for additional award administration information.

B. Administrative and National Policy Requirements

Refer to the General Application Instructions, Appendix 4, Section D, for general information regarding administrative and national policy requirements.

C. Reporting

Refer to the General Application Instructions, Appendix 4, Section E, for general information on reporting requirements.
D. Award Transfers

Changes in PI are strongly discouraged for recipients using the New Investigator Option of this award. Extenuating circumstances necessitating a change of PI will be evaluated on a case-by-case basis and at the discretion of the Grants Officer.

To assist New Investigators who are transitioning into their first independent faculty position, the submitting organization must agree to relinquish the award when the PI obtains an independent faculty position, or equivalent, at another institution so that it can be transferred to the new institution.

Refer to the General Application Instructions, Appendix 4, Section F, for general information on organization or PI changes.

VI. AGENCY CONTACTS

A. CDMRP Help Desk

Questions related to Program Announcement/Funding Opportunity content or submission requirements as well as questions related to the submission of the pre-application through the CDMRP eReceipt System should be directed to the CDMRP Help Desk, which is available Monday through Friday from 8:00 a.m. to 5:00 p.m. ET. Response times may vary depending upon the volume of inquiries.

   Phone: 301-682-5507
   Email: help@cdmrp.org

B. Grants.gov Contact Center

Questions related to application submission through the Grants.gov portal should be directed to the Grants.gov Contact Center, which is available 24 hours a day, 7 days a week (closed on U.S. federal holidays). Note that the CDMRP Help Desk is unable to provide technical assistance with Grants.gov submission.

   Phone: 800-518-4726
   Email: support@grants.gov

Sign up on Grants.gov for “send me change notification emails” by following the link on the Synopsis page for the Program Announcement/Funding Opportunity or by responding to the prompt provided by Grants.gov when first downloading the application package. If the application package is updated or changed, the original version of the application package may not be accepted by Grants.gov.
## VII. APPLICATION SUBMISSION CHECKLIST

<table>
<thead>
<tr>
<th>Grants.gov Application Components</th>
<th>Action</th>
<th>Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td>SF-424 (R&amp;R) Application for Federal Assistance Form</td>
<td>Complete form as instructed.</td>
<td></td>
</tr>
<tr>
<td>Attachments Form</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upload Project Narrative (ProjectNarrative.pdf) as Attachment 1.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upload Supporting Documentation (Support.pdf) as Attachment 2.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upload Technical Abstract (TechAbs.pdf) as Attachment 3.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upload Lay Abstract (LayAbs.pdf) as Attachment 4.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upload Statement of Work (SOW.pdf) as Attachment 5.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upload Innovation Statement (Innovation.pdf) as Attachment 7.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Investigator Option only: Upload Eligibility Statement (Eligibility.pdf) as Attachment 8.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Investigator Option only: If applicable, upload Statement of Independence (Independence.pdf) as Attachment 9.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Senior/Key Person Profile (Expanded)</td>
<td>Attach PI Biographical Sketch (Biosketch_LastName.pdf) to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach PI Previous/Current/Pending Support (Support_LastName.pdf) to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach Biographical Sketch (Biosketch_LastName.pdf) for each senior/key person to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach Previous/Current/Pending Support (Support_LastName.pdf) for each senior/key person to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Budget</td>
<td>Complete as instructed. Attach Budget Justification (BudgetJustification.pdf) to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td>Project/Performance Site Location(s) Form</td>
<td>Complete form as instructed.</td>
<td></td>
</tr>
<tr>
<td>R &amp; R Subaward Budget Attachment(s) Form</td>
<td>Complete form as instructed.</td>
<td></td>
</tr>
</tbody>
</table>